HIGHLIGHTS
- who: Ken Maes from the Laboratory for Hematology and Immunology, Department of Biomedical, Universidad de Navarra, Spain, Laboratory of Cancer Epigenetics, Centro de Investigaciou0301n Biomu00e9dica have published the article: Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential, in the Journal: (JOURNAL)
- future: Investigation is needed to better define the impact of EMA on TAM and their impact on anti-tumor immunity. Future studies would be needed to corroborate existing evidence and define most suitable combinations. egress of MDSC from bone marrow to blood and their subsequent infiltration into the tumor is promoted by proinflammatory mediators . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.